Last updated on September 2020

A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)


Brief description of study

This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.

Clinical Study Identifier: NCT03948763

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.